Altaris Acquires 51% Stake in Solesis from Michelin

Altaris Acquires Clarivate’s Life Sciences & Healthcare Segment

July 6, 2026

Data & Analytics

Clarivate agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million, with proceeds intended in part to reduce Clarivate’s debt. Altaris completed the acquisition on October 6, 2026; the business will operate independently under Altaris ownership and has approximately 2,300 employees across 22 countries.

Altaris Acquires Minaris Regenerative Medicine from Resonac

September 23, 2024

Healthcare Services

Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.

Solesis Acquires Polyzen

November 3, 2022

Medical Devices

Solesis, an operating company backed by Altaris, has acquired Polyzen, a contract developer and manufacturer of polymer-based films, coatings, components and assemblies for the medical device and biopharmaceutical markets. Polyzen will operate as a subsidiary of Solesis, expanding Solesis' polymer film and coating capabilities to better serve medical device, bioprocessing, drug delivery and cell and gene therapy customers.

Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer

December 30, 2021

Medical Devices

Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.

Altaris Capital Partners Acquires Perrigo's Prescription Pharmaceuticals Business (Padagis)

March 1, 2021

Pharmaceuticals

Altaris Capital Partners has acquired Perrigo's prescription pharmaceuticals business for $1.55 billion and completed the carve-out, renaming the business Padagis. The business, a leader in generic prescription pharmaceuticals with more than 1,300 employees across six U.S. and Israeli locations and a portfolio of 200+ product families (800 SKUs), will be headquartered in the United States as a standalone company.

Altaris Capital Partners Majority Recapitalizes Minnetronix Medical

February 3, 2021

Medical Devices

Altaris Capital Partners has completed a majority recapitalization of Minnetronix Medical, expanding a relationship in place since 2015 when Altaris was a minority investor. The transaction provides Minnetronix — a Saint Paul, Minnesota-based medical device product development and contract manufacturing partner — with capital and partnership support to accelerate its growth and product strategy.